Initial funding from PKD Foundation leads to collaboration for potential ADPKD treatment
As the PKD Foundation-funded 2014-2016 research grants concluded, rich new data were uncovered, continuing to move us closer to treatments. Among highlights are outcomes from Dr. Vishal Patel’s study, which focused on the role and function of microRNA clusters in autosomal dominant polycystic kidney disease (ADPKD).
Five potential treatments for PKD in clinical trials
Since 1982, we have led the fight against PKD through vital research funding and patient education. Today, we are encouraged by the significant strides we are making to find treatments. We have gone from a single drug in clinical trials five years ago to five drugs in trials today. Four of these drugs are considered repurposed, which shaves off millions of dollars and several years to bring them to market if they are proven effective for the treatment of PKD.
ADPKD Biomarker Summit addresses the need for clinical endpoints to clarify drug approval process
This summer we initiated, sponsored and helped facilitate the first ADPKD Biomarker Summit, where we met with representatives from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, the National Institutes of Health (NIH), and PKD experts. Eight companies including biotech start-ups and large pharmaceutical corporations interested in developing therapeutic solutions for PKD also attended.